Ethnic differences in drug metabolism

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 9, 2000, Pages 899-903

  Zhou, H H ^a   Liu, Z Q ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP2C19; CYP2D6; Drug metabolism; Ethnic differences; Gene dosage effect; Genetics polymorphism; Pharmacogenetics

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CODEINE; CYTOCHROME P450 2C19; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; DIAZEPAM; DRUG METABOLIZING ENZYME; MEPHENYTOIN; MORPHINE; NEUROLEPTIC AGENT; NORDAZEPAM; OMEPRAZOLE; PROGUANIL; PROPRANOLOL; SPARTEINE;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MUTANT; PRIORITY JOURNAL;

EID: 0033754211     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.131     Document Type: Article

References (29)

1. Ethnic differences in drug disposition and responsiveness
2. Polymorphic hydroxylation of debrisoquine in man
3. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
4. Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities
5. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
6. Nomenclature for human CYP2D6 alleles
7. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 54 alleles, their frequencies and evolution
8. Cytochrome P4502D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
9. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine
10. Molecular mechanisms of genetic polymorphisms of drug metabolism
11. Ethnic differences in response to morphine
12. Genetic polymorphism of S-mephenytoin hydroxylation
13. Pharmacogeneticy of mephenytoin: A new drug hydroxylation polymorphism in man
14. Isolation and characterization of human liver cytochrome P4502C19 correlation between 2C19 and S-mephenytoin 4'-hydroxylation
15. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans
16. Low frequency of defective alleles of cytochrome P450 enzyme 2C19 and 2D6 in the Turkish population
17. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
18. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
19. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
20. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
21. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations
22. Metroprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese
23. The mephenytoin (cytochrome P4502C19) and dextromethrophan (cytochrome P4502D6) polymorphisms in Saudi Arabians and Filipinos
24. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population
25. Individual and ethnic differences in CYP2C19 activity in Chinese populations
26. Why are diazepam metabolism and polymorphic S-meophenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations
27. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects
28. Interethnic difference in omeprazole's inhibition of diazepam metabolism
29. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions